Modeling myotonic dystrophy type 1 and type 2 (DM1 and DM2) neuropathology with IPSC-derived cortical organoids - repeat-expansion disorders myotonic dystrophy 1 and 2 (DM1, DM2) produce disabling…

Active Grant Awarded

Award ID
R21NS149030
Recipient
Awarding agency
Obligated
$233,550

Award facts

Completion date 23% complete
Place of performance
Albany, NY 12208, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke awarded Regenerative Research Foundation $233,550 on June 1, 2026. The award falls under Assistance Listing 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders, and is designated grant R21NS149030.

The grant funds research modeling myotonic dystrophy type 1 and type 2 (DM1 and DM2) neuropathology using human induced pluripotent stem cell (iPSC)-derived cortical organoids. The stated long-term objective is enabling CNS-directed therapies for myotonic dystrophy. Aim 1 tracks RNA-foci formation, splice defects, and tau aggregation at 2, 4, and 6 months in DM1, DM2, and control organoids, combining long-read RNA-seq with quantitative neuropathology. Aim 2 tests whether hyper-phosphorylated CELF2 drives glutamatergic mis-splicing. The optimized organoid protocol will be applied to DM1 iPSC lines (238-1,600 CTG repeats), DM2 lines (8.8-11.9 kb CCTG repeats), and healthy control lines.

Dollars obligated total $233,550, with an award date of June 1, 2026 and an ultimate completion date of May 31, 2028. Place of performance is Albany, New York 12208. The assistance type is Grant.

Description

Modeling myotonic dystrophy type 1 and type 2 (DM1 and DM2) neuropathology with IPSC-derived cortical organoids - repeat-expansion disorders myotonic dystrophy 1 and 2 (DM1, DM2) produce disabling cognitive and behavioral deficits, yet the molecular drivers of central-nervous-system (CNS) pathology remain undefined. DM1 is caused by expanded CTG repeats in the dystrophia-myotonica protein kinase (DMPK) gene that produces toxic CUG rnas, whereas DM2 is caused by expanded cctg repeats in the cellular nucleic-acid-binding protein (CNBP) gene that yield toxic ccug rnas. These expanded rnas sequester the splicing regulator muscleblind-like protein 1 (MBNL1), disrupt microtubule-associated protein TAU (MAPT) processing, and may provoke excitotoxicity via hyperactive CUG-binding protein elav-like family 2 (CELF2). The long-term objective is to enable CNS-directed therapies for myotonic dystrophy. The central hypothesis is that repeat-expansion RNA toxicity MIS-splices MAPT and activates CELF2-mediated glutamatergic hyperexcitability, jointly driving tauopathy and neuronal loss. This project will delineate convergent and divergent mechanisms of cortical dysfunction in DM1 and DM2 using human induced-pluripotent-stem-cell (IPSC) cortical organoids produced by an optimized protocol validated in more than sixty lines. Organoids derived from this protocol retain physiological DMPK1, CNBP, and MBNL1 expression overcoming the low expression of these genes observed in other organoid models. The optimized protocol will be applied to DM1 IPSC lines (238-1,600 CTG repeats), DM2 lines (8.8-11.9 KB cctg repeats), and healthy control lines to generate side-by-side disease and reference cortical organoids. Aim 1 will track RNA- foci formation, splice defects, and TAU aggregation at 2, 4, and 6 months in DM1, DM2, and control organoids, combining long-read RNA-SEQ with quantitative neuropathology. Aim 2 will test whether hyper-phosphorylated CELF2 drives glutamatergic MIS-splicing, network hyperexcitability, and neuronal loss across DM1 and DM2 organoids, and whether inducible shrna knock-down of CELF2 restores receptor splicing, electrophysiological balance, and TAU status relative to controls. High-density multielectrode-array recordings, long-read transcriptomics, and TAU biochemistry will integrate molecular and functional endpoints throughout the project. The study is expected to (I) establish mechanistic links between repeat RNA toxicity and tauopathy, (II) identify CELF2 as a modifiable driver of excitotoxicity, and (III) deliver a scalable, biomarker-rich organoid platform for therapeutic screening. By clarifying disease pathways and providing human assay systems, the work will accelerate the development of TAU-lowering and synapse-stabilizing strategies, directly advancing NIH priorities to translate mechanistic insight into treatments for rare neurodegenerative diseases.

Quick answers

Who received award R21NS149030?

R21NS149030 was awarded to Regenerative Research Foundation by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on June 1, 2026.

How much is award R21NS149030 worth?

$233,550 has been obligated on R21NS149030.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award